VentrAssist ™ Features at International Medical Conference
Sydney, 6 April 2003: Ventracor Limited (ASX:VCR) will be showcased to
leading medical professionals from around the world at the International
Society of Heart & Lung Transplantation (ISHLT) annual meeting in the United
States this month.
The April 19 – 24 meeting in San Francisco will focus on the latest practices,
emerging technologies and medical advances in the treatment of end-stage
heart and lung disease.
Ventracor will be the only Australian participant in this prestigious event and
will update targeted medical audiences on its VentrAssist™ ‘artificial heart’ – a
third generation left ventricular assist system (LVAS) with a unique design
which features only one moving part.
The VentrAssist™ LVAS provides left heart support and is designed as a
permanent alternative to heart transplantation for hundreds of thousands of
patients worldwide suffering end stage heart failure.
A Pilot Trial to establish the safety of the VentrAssist™ is being conducted at
The Alfred hospital in Melbourne.
A trial to gather clinical data to support European approval is due to begin this
July.
ISHLT is the world’s leading organization for the professional education of
medical professionals involved in heart and lung transplantation
(www.ishlt.org).
For further information, please contact:
Andrew Geddes
Manager, Investor Relations
Ventracor Limited
(02) 9406 3086
VCR
ventracor limited
